News InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904 Continue Reading Previous InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904Next Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors Related Stories Identity Verification News Security Gartner® Names Keeper Security the Second Fastest-Growing Company in the Market Share Analysis: Security Software, Worldwide, 2025 News QCI Redefines Advantage Play Intelligence with MCP-Driven Agentic AI News Expedience Software Introduces CRM Connect to Extend Microsoft Dynamics Document Generation News Industrial AI Provider Protex AI Launches New Certification to Empower Safety Leaders with Privacy-First Safety AI News iSolutions Recognized Across G2 Summer 2026 Reports for AR Automation and ERP Excellence News Canyon GBS Acquires Apidapter, Inc., Expanding Integration Capabilities for Higher Education Customers
